[go: up one dir, main page]

EA200701084A1 - Поливалентные вакцины, содержащие рекомбинантные вирусные векторы - Google Patents

Поливалентные вакцины, содержащие рекомбинантные вирусные векторы

Info

Publication number
EA200701084A1
EA200701084A1 EA200701084A EA200701084A EA200701084A1 EA 200701084 A1 EA200701084 A1 EA 200701084A1 EA 200701084 A EA200701084 A EA 200701084A EA 200701084 A EA200701084 A EA 200701084A EA 200701084 A1 EA200701084 A1 EA 200701084A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigens
cleavage
relates
present
vaccines containing
Prior art date
Application number
EA200701084A
Other languages
English (en)
Other versions
EA012037B1 (ru
Inventor
Мензо Янс Эмко Хавенга
Роналд Вогелс
Джералд Сэдофф
Дэвид Хоун
Ясир Абдул Вахид Скейки
Катарина Радошевич
Original Assignee
Круселл Холланд Б.В.
ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В., ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН filed Critical Круселл Холланд Б.В.
Publication of EA200701084A1 publication Critical patent/EA200701084A1/ru
Publication of EA012037B1 publication Critical patent/EA012037B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к вакцинам, содержащим рекомбинантные векторы, такие как рекомбинантные аденовирусы. Векторы содержат гетерологичные последовательности нуклеиновых кислот, кодирующие по меньшей мере два антигена из одной или более вызывающих туберкулез бациллы. Настоящее изобретение относится также к применению специфических сайтов узнавания протеаз, связывающих антигены, посредством которых кодируемые антигены разделяются после расщепления. После расщепления антигены способствуют иммунному ответу раздельным образом. Рекомбинантные векторы могут содержать нуклеиновую кислоту, кодирующую расщепление линкеров и разделение антигенов под действием протеаз. Кроме того, настоящее изобретение относится к применению генетических адъювантов, кодируемых рекомбинантными векторами, при котором такие генетические адъюванты могут быть также расщеплены при наличии расщепляющих линкеров и специфической протеазы.
EA200701084A 2004-11-16 2005-11-15 Поливалентные вакцины, содержащие рекомбинантные вирусные векторы EA012037B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62825304P 2004-11-16 2004-11-16
EP04106074 2004-11-25
US65111305P 2005-02-08 2005-02-08
PCT/EP2005/055984 WO2006053871A2 (en) 2004-11-16 2005-11-15 Multivalent vaccines comprising recombinant viral vectors

Publications (2)

Publication Number Publication Date
EA200701084A1 true EA200701084A1 (ru) 2007-10-26
EA012037B1 EA012037B1 (ru) 2009-06-30

Family

ID=34929936

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701084A EA012037B1 (ru) 2004-11-16 2005-11-15 Поливалентные вакцины, содержащие рекомбинантные вирусные векторы

Country Status (14)

Country Link
US (3) US8012467B2 (ru)
EP (1) EP1812580B1 (ru)
JP (1) JP4838259B2 (ru)
KR (1) KR101255870B1 (ru)
CN (2) CN102220357B (ru)
AU (2) AU2005305869B2 (ru)
BR (1) BRPI0518933A2 (ru)
CA (1) CA2586620C (ru)
EA (1) EA012037B1 (ru)
MX (1) MX2007005256A (ru)
NZ (2) NZ555907A (ru)
SG (2) SG159554A1 (ru)
WO (1) WO2006053871A2 (ru)
ZA (1) ZA200703838B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
KR101255870B1 (ko) 2004-11-16 2013-04-17 아에라스 글로벌 티비 백신 파운데이션 재조합 바이러스 벡터를 포함하는 다가 백신
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
EA016818B1 (ru) * 2007-01-15 2012-07-30 Глаксосмитклайн Байолоджикалс С.А. Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
DK2604695T3 (da) 2007-12-27 2023-01-16 Univ Zuerich Replikationsdefekte arenavirusvektorer
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
JP5984388B2 (ja) * 2008-07-16 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
ES2699685T3 (es) 2008-11-18 2019-02-12 Beth Israel Deaconess Medical Ct Inc Vacunas antivíricas con inmunogenicidad celular mejorada
TR201903223T4 (tr) * 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EA201390424A1 (ru) 2010-09-20 2013-07-30 Круселл Холланд Б.В. Терапевтическая вакцинация против активного туберкулеза
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
EP2838990A4 (en) * 2012-04-16 2016-08-10 Aeras Global Tb Vaccine Found RECOMBINANT MYCOBACTERIUM FOR THE CODING OF A HEPARIN-BINDING HEMAGGLUTININE (HBHA) FUSION PROTEIN AND USES THEREOF
EP2872172B1 (en) 2012-07-10 2018-11-14 Transgene SA Mycobacterial antigen vaccine
WO2014140301A1 (en) * 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
CN103304670B (zh) * 2013-06-03 2015-09-16 中国人民解放军第三〇九医院 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用
SI3046536T1 (sl) 2013-09-19 2019-05-31 Janssen Vaccines & Prevention B.V. Izboljšane formulacije adenovirusa
CN103865934B (zh) * 2014-03-26 2017-02-22 中国人民解放军成都军区疾病预防控制中心 银环毒素抗原表位基因及其在基因疫苗及抗原制备中的应用
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2015279086B2 (en) 2014-06-26 2021-01-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016198599A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
BR112018006488B1 (pt) 2015-10-06 2024-03-12 Janssen Vaccines & Prevention B.V. Métodos para prevenir a degradação induzida por plástico de biológicos
ES2829272T3 (es) 2016-05-12 2021-05-31 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado
AU2017283118B2 (en) 2016-06-20 2019-02-07 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CN106754758A (zh) * 2016-12-29 2017-05-31 汕头大学医学院 一种含细胞因子佐剂的重组肠道病毒表型混合系统的构建方法及其应用
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
CN107365365B (zh) * 2017-08-30 2021-01-01 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
CN107602672B (zh) * 2017-08-30 2021-06-18 广州医科大学附属第一医院 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法
US11389525B2 (en) 2017-10-27 2022-07-19 Statens Serum Institut Polygene influenza vaccine
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
WO2024155646A1 (en) * 2023-01-17 2024-07-25 Regents Of The University Of Minnesota Multivalent vaccines against tuberculosis

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631460B2 (en) 1989-09-19 1992-11-26 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
EP0499003A1 (en) 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
WO1995014713A2 (en) 1993-11-23 1995-06-01 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AU6024596A (en) 1995-05-23 1996-12-11 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) * 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
PT1203817E (pt) 1995-09-01 2006-08-31 Corixa Corp Compostos e metodos para imunoterapia e le diagnostic de tuberculose
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
DE69636075D1 (de) 1995-09-01 2006-06-01 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US6087163A (en) * 1997-02-06 2000-07-11 The Public Health Research Institute Of The City Of New York, Inc. Mycobacterium tuberculosis specific proteins and genes, mixtures of anitgens and uses thereof
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
EP0934415A2 (en) 1996-10-11 1999-08-11 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU6029898A (en) 1997-01-21 1998-08-07 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
DE69838268T2 (de) 1997-04-02 2008-05-08 Statens Serum Institut Immonologisch aktiven, neuen Polypeptidefragmenten
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
AU8123898A (en) 1997-07-16 1999-02-10 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as metho ds usingthe same
NZ504951A (en) 1997-11-10 2001-06-29 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
TWI243169B (en) 1998-03-02 2005-11-11 Nissan Chemical Ind Ltd Optically active epoxy compound
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
US20020150592A1 (en) * 1998-09-18 2002-10-17 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
EP1117683A2 (en) 1998-10-08 2001-07-25 Statens Serum Institut Tb vaccine and diagnostic based on antigens from the m. tuberculosis cell
US6465633B1 (en) * 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
AU2594500A (en) 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
US20030027774A1 (en) 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
PT1816205E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante baseado no serótipo 48 (ad48)
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP5010079B2 (ja) 1999-07-13 2012-08-29 スタテンズ セーラム インスティテュート マイコバクテリウム・ツベルクローシスｅｓａｔ−６遺伝子ファミリーベースの結核ワクチン及び診断法
US20020039583A1 (en) 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
CA2386841A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
PT1517913E (pt) 1999-10-07 2007-05-31 Corixa Corp Sequência codificante de mycobacterium turberculosis para expressão de proteínas heterólogas.
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006693D0 (en) 2000-03-20 2000-05-10 Glaxo Group Ltd Vaccine
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
US7754201B2 (en) * 2000-06-02 2010-07-13 GenPhar, Inc Method of vaccination through serotype rotation
AU6867801A (en) 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
JP4399255B2 (ja) 2001-06-22 2010-01-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 細菌の形質転換体を迅速に選別する方法および新規なサルアデノウイルス蛋白質
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
JP2006513714A (ja) 2003-03-17 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド アデノウイルス血清型２４ベクター、核酸およびそれにより製造されたウイルス
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
KR100992646B1 (ko) * 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
US20060216272A1 (en) * 2003-09-18 2006-09-28 Emini Emilio A Therapeutic immunization of hiv-infected individuals
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
KR101255870B1 (ko) 2004-11-16 2013-04-17 아에라스 글로벌 티비 백신 파운데이션 재조합 바이러스 벡터를 포함하는 다가 백신
KR101329323B1 (ko) * 2004-12-01 2013-11-14 아에라스 글로벌 티비 백신 파운데이션 엔도솜을 이탈하는 능력이 보강된 재조합 비씨지 균주
SG164383A1 (en) 2005-07-21 2010-09-29 Abbott Lab Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis

Also Published As

Publication number Publication date
EP1812580B1 (en) 2014-12-17
CA2586620A1 (en) 2006-05-26
BRPI0518933A2 (pt) 2008-12-16
NZ555907A (en) 2009-12-24
CN102220357B (zh) 2013-12-25
KR101255870B1 (ko) 2013-04-17
AU2005305869A1 (en) 2006-05-26
US8202723B2 (en) 2012-06-19
AU2011200749A1 (en) 2011-03-10
US20110256166A1 (en) 2011-10-20
CN101090974A (zh) 2007-12-19
ZA200703838B (en) 2012-07-25
AU2011200749B2 (en) 2012-03-01
NZ581306A (en) 2011-03-31
CN101090974B (zh) 2011-05-11
WO2006053871A3 (en) 2006-12-21
SG159555A1 (en) 2010-03-30
EA012037B1 (ru) 2009-06-30
MX2007005256A (es) 2008-03-11
AU2011200749B9 (en) 2012-04-05
US8012467B2 (en) 2011-09-06
JP4838259B2 (ja) 2011-12-14
US20090123438A1 (en) 2009-05-14
KR20070091620A (ko) 2007-09-11
JP2008520198A (ja) 2008-06-19
AU2005305869B2 (en) 2010-12-09
US8609402B2 (en) 2013-12-17
CA2586620C (en) 2014-06-03
CN102220357A (zh) 2011-10-19
EP1812580A2 (en) 2007-08-01
SG159554A1 (en) 2010-03-30
WO2006053871A2 (en) 2006-05-26
US20110281347A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
EA200701084A1 (ru) Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
NO20072470L (no) Malariaigangsetter/forsterkervaksine
NZ757882A (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
EA200870237A1 (ru) Последовательности пептидов и композиции
WO2005012537A3 (en) Adenoviral vector-based vaccines
EA200901060A1 (ru) Новый способ и композиции
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
NO20071523L (no) Vaksiner
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
WO2021239838A3 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
EP1530637A4 (en) SUBTILISIN CARLSBERG PROTEINS WITH REDUCED IMMUNOGENICITY
WO2018172259A3 (en) IMPROVED LI VACCINE ADJUVANT
WO2001074845A3 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
MX2010010025A (es) Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones.
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
SE0102410D0 (sv) Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2001076622A3 (en) Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof
WO2004052914A3 (en) Compositions and methods for inhibiting malaria protease falcipain-2
WO2011133870A3 (en) Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)
WO2005062871A3 (en) Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
WO2008027414A3 (en) Novel p. falciparum vaccine proteins and coding sequences
SE9900674D0 (sv) Mite protein